http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 01 Jul 2026 06:48:10 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Investing/Galderma+falls+after+FDA+issues+second+setback+for+Botox+rival/26716560.html <p data-start="199" data-end="467">Investing.com -- Swiss dermatology companyGalderma Group AG (SIX:GALD) fell nearly 6% on Wednesday after the U.S. Food and Drug Administration declined to approve its wrinkle treatment RelabotulinumtoxinA, delaying the product&amp;#39;s planned entry into the U.S. aesthetics market.</p> <p data-start="469" data-end="629">The stock dropped 5.8% to CHF 173.25, sharply underperforming the benchmark SMI which traded little changed in afternoon dealings.</p> <p data-start="469" data-end="629"></p> <p data-start="631" data-end="1003">The FDA issued a Complete Response Letter, citing manufacturing-related observations identified during inspections conducted as part of its review. The decision marks the second time the regulator has declined the application after a similar manufacturing-related setback in 2023, although the http://www.streetinsider.com/Investing/Galderma+falls+after+FDA+issues+second+setback+for+Botox+rival/26716560.html Wed, 01 Jul 2026 06:48:10 -0400 GALD http://www.streetinsider.com/General+News/Galderma+falls+after+FDA+issues+second+setback+for+Botox+rival/26716560.html <p data-start="199" data-end="467">Investing.com -- Swiss dermatology companyGalderma Group AG (SIX:GALD) fell nearly 6% on Wednesday after the U.S. Food and Drug Administration declined to approve its wrinkle treatment RelabotulinumtoxinA, delaying the product&amp;#39;s planned entry into the U.S. aesthetics market.</p> <p data-start="469" data-end="629">The stock dropped 5.8% to CHF 173.25, sharply underperforming the benchmark SMI which traded little changed in afternoon dealings.</p> <p data-start="469" data-end="629"></p> <p data-start="631" data-end="1003">The FDA issued a Complete Response Letter, citing manufacturing-related observations identified during inspections conducted as part of its review. The decision marks the second time the regulator has declined the application after a similar manufacturing-related setback in 2023, although the http://www.streetinsider.com/General+News/Galderma+falls+after+FDA+issues+second+setback+for+Botox+rival/26716560.html Wed, 01 Jul 2026 06:48:10 -0400 GALD http://www.streetinsider.com/Press+Releases/Galderma+Provides+Progress+Update+Regarding+RelabotulinumtoxinA+Regulatory+Submission+in+the+United+States/26715506.html <ul class="bwlistdisc"> <li> Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization </li> <li> Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback </li> <li> Regulatory filings in other territories are ongoing and remain on track </li> </ul><p> <i>Ad hoc announcement pursuant to Art. 53 LR</i> </p> <p> ZUG, Switzerland--(BUSINESS WIRE)-- Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. http://www.streetinsider.com/Press+Releases/Galderma+Provides+Progress+Update+Regarding+RelabotulinumtoxinA+Regulatory+Submission+in+the+United+States/26715506.html Wed, 01 Jul 2026 01:00:00 -0400 A.06822034 GALD O.20026344 O.53383194 http://www.streetinsider.com/Press+Releases/Galderma+Provides+Progress+Update+Regarding+RelabotulinumtoxinA+Regulatory+Submission+in+the+United+States/26715506.html <ul class="bwlistdisc"> <li> Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization </li> <li> Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback </li> <li> Regulatory filings in other territories are ongoing and remain on track </li> </ul><p> <i>Ad hoc announcement pursuant to Art. 53 LR</i> </p> <p> ZUG, Switzerland--(BUSINESS WIRE)-- Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. http://www.streetinsider.com/Press+Releases/Galderma+Provides+Progress+Update+Regarding+RelabotulinumtoxinA+Regulatory+Submission+in+the+United+States/26715506.html Wed, 01 Jul 2026 01:00:00 -0400 A.06822034 GALD O.20026344 O.53383194 http://www.streetinsider.com/Press+Releases/Galderma+Provides+Progress+Update+Regarding+RelabotulinumtoxinA+Regulatory+Submission+in+the+United+States/26715506.html <ul class="bwlistdisc"> <li> Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization </li> <li> Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback </li> <li> Regulatory filings in other territories are ongoing and remain on track </li> </ul><p> <i>Ad hoc announcement pursuant to Art. 53 LR</i> </p> <p> ZUG, Switzerland--(BUSINESS WIRE)-- Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. http://www.streetinsider.com/Press+Releases/Galderma+Provides+Progress+Update+Regarding+RelabotulinumtoxinA+Regulatory+Submission+in+the+United+States/26715506.html Wed, 01 Jul 2026 01:00:00 -0400 A.06822034 GALD O.20026344 O.53383194 http://www.streetinsider.com/Press+Releases/Galderma+Provides+Progress+Update+Regarding+RelabotulinumtoxinA+Regulatory+Submission+in+the+United+States/26715506.html <ul class="bwlistdisc"> <li> Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization </li> <li> Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback </li> <li> Regulatory filings in other territories are ongoing and remain on track </li> </ul><p> <i>Ad hoc announcement pursuant to Art. 53 LR</i> </p> <p> ZUG, Switzerland--(BUSINESS WIRE)-- Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. http://www.streetinsider.com/Press+Releases/Galderma+Provides+Progress+Update+Regarding+RelabotulinumtoxinA+Regulatory+Submission+in+the+United+States/26715506.html Wed, 01 Jul 2026 01:00:00 -0400 A.06822034 GALD O.20026344 O.53383194 http://www.streetinsider.com/Business+Wire/Galderma+Provides+Progress+Update+Regarding+RelabotulinumtoxinA+Regulatory+Submission+in+the+United+States/26715506.html <ul class="bwlistdisc"> <li> Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization </li> <li> Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback </li> <li> Regulatory filings in other territories are ongoing and remain on track </li> </ul><p> <i>Ad hoc announcement pursuant to Art. 53 LR</i> </p> <p> ZUG, Switzerland--(BUSINESS WIRE)-- Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. http://www.streetinsider.com/Business+Wire/Galderma+Provides+Progress+Update+Regarding+RelabotulinumtoxinA+Regulatory+Submission+in+the+United+States/26715506.html Wed, 01 Jul 2026 01:00:00 -0400 A.06822034 GALD O.20026344 O.53383194 http://www.streetinsider.com/Business+Wire/Galderma+Provides+Progress+Update+Regarding+RelabotulinumtoxinA+Regulatory+Submission+in+the+United+States/26715506.html <ul class="bwlistdisc"> <li> Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization </li> <li> Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback </li> <li> Regulatory filings in other territories are ongoing and remain on track </li> </ul><p> <i>Ad hoc announcement pursuant to Art. 53 LR</i> </p> <p> ZUG, Switzerland--(BUSINESS WIRE)-- Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. http://www.streetinsider.com/Business+Wire/Galderma+Provides+Progress+Update+Regarding+RelabotulinumtoxinA+Regulatory+Submission+in+the+United+States/26715506.html Wed, 01 Jul 2026 01:00:00 -0400 A.06822034 GALD O.20026344 O.53383194 http://www.streetinsider.com/Business+Wire/Galderma+Provides+Progress+Update+Regarding+RelabotulinumtoxinA+Regulatory+Submission+in+the+United+States/26715506.html <ul class="bwlistdisc"> <li> Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization </li> <li> Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback </li> <li> Regulatory filings in other territories are ongoing and remain on track </li> </ul><p> <i>Ad hoc announcement pursuant to Art. 53 LR</i> </p> <p> ZUG, Switzerland--(BUSINESS WIRE)-- Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. http://www.streetinsider.com/Business+Wire/Galderma+Provides+Progress+Update+Regarding+RelabotulinumtoxinA+Regulatory+Submission+in+the+United+States/26715506.html Wed, 01 Jul 2026 01:00:00 -0400 A.06822034 GALD O.20026344 O.53383194 http://www.streetinsider.com/Business+Wire/Galderma+Provides+Progress+Update+Regarding+RelabotulinumtoxinA+Regulatory+Submission+in+the+United+States/26715506.html <ul class="bwlistdisc"> <li> Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization </li> <li> Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback </li> <li> Regulatory filings in other territories are ongoing and remain on track </li> </ul><p> <i>Ad hoc announcement pursuant to Art. 53 LR</i> </p> <p> ZUG, Switzerland--(BUSINESS WIRE)-- Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. http://www.streetinsider.com/Business+Wire/Galderma+Provides+Progress+Update+Regarding+RelabotulinumtoxinA+Regulatory+Submission+in+the+United+States/26715506.html Wed, 01 Jul 2026 01:00:00 -0400 A.06822034 GALD O.20026344 O.53383194 http://www.streetinsider.com/Press+Releases/Galderma+Unveils+New+Global+Survey+Data+Exploring+the+Evolving+Expectations+and+Experiences+of+Patients+and+Healthcare+Professionals+With+Anti-wrinkle+Treatments/26631490.html <ul class="bwlistdisc"> <li> Results from Galderma’s global survey showed that performance is the top priority for healthcare professionals (HCPs), with long-lasting results, pure, highly active formulations, and fast onset cited as the leading criteria for recommending a treatment1 </li> <li> Reliable clinical outcomes and robust clinical trials were the top two pillars of confidence for HCPs when selecting an anti-wrinkle treatment </li> <li> Ready-to-use liquid formulations are also gaining traction as a key treatment benefit when considering switching to new products1 </li> <li> Patients also rank long-lasting and natural-looking results as the most important benefits when selecting a treatment, and cite increased confidence, improved appearance, and overall well-being as benefits they http://www.streetinsider.com/Press+Releases/Galderma+Unveils+New+Global+Survey+Data+Exploring+the+Evolving+Expectations+and+Experiences+of+Patients+and+Healthcare+Professionals+With+Anti-wrinkle+Treatments/26631490.html Thu, 11 Jun 2026 01:00:00 -0400 GALD O.53383194 http://www.streetinsider.com/Press+Releases/Galderma+Unveils+New+Global+Survey+Data+Exploring+the+Evolving+Expectations+and+Experiences+of+Patients+and+Healthcare+Professionals+With+Anti-wrinkle+Treatments/26631490.html <ul class="bwlistdisc"> <li> Results from Galderma’s global survey showed that performance is the top priority for healthcare professionals (HCPs), with long-lasting results, pure, highly active formulations, and fast onset cited as the leading criteria for recommending a treatment1 </li> <li> Reliable clinical outcomes and robust clinical trials were the top two pillars of confidence for HCPs when selecting an anti-wrinkle treatment </li> <li> Ready-to-use liquid formulations are also gaining traction as a key treatment benefit when considering switching to new products1 </li> <li> Patients also rank long-lasting and natural-looking results as the most important benefits when selecting a treatment, and cite increased confidence, improved appearance, and overall well-being as benefits they http://www.streetinsider.com/Press+Releases/Galderma+Unveils+New+Global+Survey+Data+Exploring+the+Evolving+Expectations+and+Experiences+of+Patients+and+Healthcare+Professionals+With+Anti-wrinkle+Treatments/26631490.html Thu, 11 Jun 2026 01:00:00 -0400 GALD O.53383194 http://www.streetinsider.com/Business+Wire/Galderma+Unveils+New+Global+Survey+Data+Exploring+the+Evolving+Expectations+and+Experiences+of+Patients+and+Healthcare+Professionals+With+Anti-wrinkle+Treatments/26631490.html <ul class="bwlistdisc"> <li> Results from Galderma’s global survey showed that performance is the top priority for healthcare professionals (HCPs), with long-lasting results, pure, highly active formulations, and fast onset cited as the leading criteria for recommending a treatment1 </li> <li> Reliable clinical outcomes and robust clinical trials were the top two pillars of confidence for HCPs when selecting an anti-wrinkle treatment </li> <li> Ready-to-use liquid formulations are also gaining traction as a key treatment benefit when considering switching to new products1 </li> <li> Patients also rank long-lasting and natural-looking results as the most important benefits when selecting a treatment, and cite increased confidence, improved appearance, and overall well-being as benefits they http://www.streetinsider.com/Business+Wire/Galderma+Unveils+New+Global+Survey+Data+Exploring+the+Evolving+Expectations+and+Experiences+of+Patients+and+Healthcare+Professionals+With+Anti-wrinkle+Treatments/26631490.html Thu, 11 Jun 2026 01:00:00 -0400 GALD O.53383194 http://www.streetinsider.com/Business+Wire/Galderma+Unveils+New+Global+Survey+Data+Exploring+the+Evolving+Expectations+and+Experiences+of+Patients+and+Healthcare+Professionals+With+Anti-wrinkle+Treatments/26631490.html <ul class="bwlistdisc"> <li> Results from Galderma’s global survey showed that performance is the top priority for healthcare professionals (HCPs), with long-lasting results, pure, highly active formulations, and fast onset cited as the leading criteria for recommending a treatment1 </li> <li> Reliable clinical outcomes and robust clinical trials were the top two pillars of confidence for HCPs when selecting an anti-wrinkle treatment </li> <li> Ready-to-use liquid formulations are also gaining traction as a key treatment benefit when considering switching to new products1 </li> <li> Patients also rank long-lasting and natural-looking results as the most important benefits when selecting a treatment, and cite increased confidence, improved appearance, and overall well-being as benefits they http://www.streetinsider.com/Business+Wire/Galderma+Unveils+New+Global+Survey+Data+Exploring+the+Evolving+Expectations+and+Experiences+of+Patients+and+Healthcare+Professionals+With+Anti-wrinkle+Treatments/26631490.html Thu, 11 Jun 2026 01:00:00 -0400 GALD O.53383194 http://www.streetinsider.com/FDA/Galderma+gets+FDA+approval+for+prescription+acne+gel+to+go+OTC/26540230.html <p>Galderma (SIX: GALD) received U.S. Food and Drug Administration approval to sell its Differin Epiduo Acne Gel over-the-counter for patients 12 years and older, marking a prescription-to-OTC transition for the acne treatment.</p> <p>The gel combines adapalene 0.1% and benzoyl peroxide 2.5%, ingredients that address multiple causes of acne including clogged pores, acne-causing bacteria, and inflammation. The formulation was originally the first FDA-approved stable, fixed-dose prescription acne treatment to combine benzoyl peroxide with a retinoid.</p> <p>Clinical studies showed the combination treatment outperformed its individual active ingredients and placebo across inflammatory, non-inflammatory, and total acne lesions. The studies demonstrated up to 70.3% reduction in http://www.streetinsider.com/FDA/Galderma+gets+FDA+approval+for+prescription+acne+gel+to+go+OTC/26540230.html Fri, 22 May 2026 12:25:18 -0400 A.06822034 A.50213547 GALD O.20026344 O.46818259 O.53383194 http://www.streetinsider.com/FDA/Galderma+gets+FDA+approval+for+prescription+acne+gel+to+go+OTC/26540230.html <p>Galderma (SIX: GALD) received U.S. Food and Drug Administration approval to sell its Differin Epiduo Acne Gel over-the-counter for patients 12 years and older, marking a prescription-to-OTC transition for the acne treatment.</p> <p>The gel combines adapalene 0.1% and benzoyl peroxide 2.5%, ingredients that address multiple causes of acne including clogged pores, acne-causing bacteria, and inflammation. The formulation was originally the first FDA-approved stable, fixed-dose prescription acne treatment to combine benzoyl peroxide with a retinoid.</p> <p>Clinical studies showed the combination treatment outperformed its individual active ingredients and placebo across inflammatory, non-inflammatory, and total acne lesions. The studies demonstrated up to 70.3% reduction in http://www.streetinsider.com/FDA/Galderma+gets+FDA+approval+for+prescription+acne+gel+to+go+OTC/26540230.html Fri, 22 May 2026 12:25:18 -0400 A.06822034 A.50213547 GALD O.20026344 O.46818259 O.53383194 http://www.streetinsider.com/FDA/Galderma+gets+FDA+approval+for+prescription+acne+gel+to+go+OTC/26540230.html <p>Galderma (SIX: GALD) received U.S. Food and Drug Administration approval to sell its Differin Epiduo Acne Gel over-the-counter for patients 12 years and older, marking a prescription-to-OTC transition for the acne treatment.</p> <p>The gel combines adapalene 0.1% and benzoyl peroxide 2.5%, ingredients that address multiple causes of acne including clogged pores, acne-causing bacteria, and inflammation. The formulation was originally the first FDA-approved stable, fixed-dose prescription acne treatment to combine benzoyl peroxide with a retinoid.</p> <p>Clinical studies showed the combination treatment outperformed its individual active ingredients and placebo across inflammatory, non-inflammatory, and total acne lesions. The studies demonstrated up to 70.3% reduction in http://www.streetinsider.com/FDA/Galderma+gets+FDA+approval+for+prescription+acne+gel+to+go+OTC/26540230.html Fri, 22 May 2026 12:25:18 -0400 A.06822034 A.50213547 GALD O.20026344 O.46818259 O.53383194 http://www.streetinsider.com/FDA/Galderma+gets+FDA+approval+for+prescription+acne+gel+to+go+OTC/26540230.html <p>Galderma (SIX: GALD) received U.S. Food and Drug Administration approval to sell its Differin Epiduo Acne Gel over-the-counter for patients 12 years and older, marking a prescription-to-OTC transition for the acne treatment.</p> <p>The gel combines adapalene 0.1% and benzoyl peroxide 2.5%, ingredients that address multiple causes of acne including clogged pores, acne-causing bacteria, and inflammation. The formulation was originally the first FDA-approved stable, fixed-dose prescription acne treatment to combine benzoyl peroxide with a retinoid.</p> <p>Clinical studies showed the combination treatment outperformed its individual active ingredients and placebo across inflammatory, non-inflammatory, and total acne lesions. The studies demonstrated up to 70.3% reduction in http://www.streetinsider.com/FDA/Galderma+gets+FDA+approval+for+prescription+acne+gel+to+go+OTC/26540230.html Fri, 22 May 2026 12:25:18 -0400 A.06822034 A.50213547 GALD O.20026344 O.46818259 O.53383194 http://www.streetinsider.com/FDA/Galderma+gets+FDA+approval+for+prescription+acne+gel+to+go+OTC/26540230.html <p>Galderma (SIX: GALD) received U.S. Food and Drug Administration approval to sell its Differin Epiduo Acne Gel over-the-counter for patients 12 years and older, marking a prescription-to-OTC transition for the acne treatment.</p> <p>The gel combines adapalene 0.1% and benzoyl peroxide 2.5%, ingredients that address multiple causes of acne including clogged pores, acne-causing bacteria, and inflammation. The formulation was originally the first FDA-approved stable, fixed-dose prescription acne treatment to combine benzoyl peroxide with a retinoid.</p> <p>Clinical studies showed the combination treatment outperformed its individual active ingredients and placebo across inflammatory, non-inflammatory, and total acne lesions. The studies demonstrated up to 70.3% reduction in http://www.streetinsider.com/FDA/Galderma+gets+FDA+approval+for+prescription+acne+gel+to+go+OTC/26540230.html Fri, 22 May 2026 12:25:18 -0400 A.06822034 A.50213547 GALD O.20026344 O.46818259 O.53383194 http://www.streetinsider.com/FDA/Galderma+gets+FDA+approval+for+prescription+acne+gel+to+go+OTC/26540230.html <p>Galderma (SIX: GALD) received U.S. Food and Drug Administration approval to sell its Differin Epiduo Acne Gel over-the-counter for patients 12 years and older, marking a prescription-to-OTC transition for the acne treatment.</p> <p>The gel combines adapalene 0.1% and benzoyl peroxide 2.5%, ingredients that address multiple causes of acne including clogged pores, acne-causing bacteria, and inflammation. The formulation was originally the first FDA-approved stable, fixed-dose prescription acne treatment to combine benzoyl peroxide with a retinoid.</p> <p>Clinical studies showed the combination treatment outperformed its individual active ingredients and placebo across inflammatory, non-inflammatory, and total acne lesions. The studies demonstrated up to 70.3% reduction in http://www.streetinsider.com/FDA/Galderma+gets+FDA+approval+for+prescription+acne+gel+to+go+OTC/26540230.html Fri, 22 May 2026 12:25:18 -0400 A.06822034 A.50213547 GALD O.20026344 O.46818259 O.53383194 http://www.streetinsider.com/Press+Releases/Galderma+Receives+U.S.+FDA+Approval+for+Differin%C2%AE+Epiduo%C2%AE+Acne+Gel+Prescription-to-OTC+Switch/26540226.html <ul class="bwlistdisc"> <li> A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older </li> <li> Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage </li> <li> Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter </li> <li> The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients http://www.streetinsider.com/Press+Releases/Galderma+Receives+U.S.+FDA+Approval+for+Differin%C2%AE+Epiduo%C2%AE+Acne+Gel+Prescription-to-OTC+Switch/26540226.html Fri, 22 May 2026 12:25:00 -0400 A.06822034 A.50213547 GALD O.20026344 O.46818259 O.53383194 http://www.streetinsider.com/Press+Releases/Galderma+Receives+U.S.+FDA+Approval+for+Differin%C2%AE+Epiduo%C2%AE+Acne+Gel+Prescription-to-OTC+Switch/26540226.html <ul class="bwlistdisc"> <li> A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older </li> <li> Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage </li> <li> Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter </li> <li> The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients http://www.streetinsider.com/Press+Releases/Galderma+Receives+U.S.+FDA+Approval+for+Differin%C2%AE+Epiduo%C2%AE+Acne+Gel+Prescription-to-OTC+Switch/26540226.html Fri, 22 May 2026 12:25:00 -0400 A.06822034 A.50213547 GALD O.20026344 O.46818259 O.53383194 http://www.streetinsider.com/Press+Releases/Galderma+Receives+U.S.+FDA+Approval+for+Differin%C2%AE+Epiduo%C2%AE+Acne+Gel+Prescription-to-OTC+Switch/26540226.html <ul class="bwlistdisc"> <li> A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older </li> <li> Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage </li> <li> Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter </li> <li> The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients http://www.streetinsider.com/Press+Releases/Galderma+Receives+U.S.+FDA+Approval+for+Differin%C2%AE+Epiduo%C2%AE+Acne+Gel+Prescription-to-OTC+Switch/26540226.html Fri, 22 May 2026 12:25:00 -0400 A.06822034 A.50213547 GALD O.20026344 O.46818259 O.53383194 http://www.streetinsider.com/Press+Releases/Galderma+Receives+U.S.+FDA+Approval+for+Differin%C2%AE+Epiduo%C2%AE+Acne+Gel+Prescription-to-OTC+Switch/26540226.html <ul class="bwlistdisc"> <li> A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older </li> <li> Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage </li> <li> Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter </li> <li> The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients http://www.streetinsider.com/Press+Releases/Galderma+Receives+U.S.+FDA+Approval+for+Differin%C2%AE+Epiduo%C2%AE+Acne+Gel+Prescription-to-OTC+Switch/26540226.html Fri, 22 May 2026 12:25:00 -0400 A.06822034 A.50213547 GALD O.20026344 O.46818259 O.53383194 http://www.streetinsider.com/Press+Releases/Galderma+Receives+U.S.+FDA+Approval+for+Differin%C2%AE+Epiduo%C2%AE+Acne+Gel+Prescription-to-OTC+Switch/26540226.html <ul class="bwlistdisc"> <li> A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older </li> <li> Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage </li> <li> Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter </li> <li> The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients http://www.streetinsider.com/Press+Releases/Galderma+Receives+U.S.+FDA+Approval+for+Differin%C2%AE+Epiduo%C2%AE+Acne+Gel+Prescription-to-OTC+Switch/26540226.html Fri, 22 May 2026 12:25:00 -0400 A.06822034 A.50213547 GALD O.20026344 O.46818259 O.53383194